Vascular endothelial growth factor inhibition and anticoagulation: focus on mucosal bleeding and platelet count

Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors

2026

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

10.1111/jth.13140 · 2015

10.1111/j.1538-7836.2005.01204.x

10.1111/j.1538-7836.2005.01204.x · 2005

Mechanisms of adverse effects of anti-VEGF therapy for cancer

10.1038/sj.bjc.6603813 · 2007

Weibel-Palade bodies orchestrate pericytes during angiogenesis

10.1161/atvbaha.119.313021 · 2019

Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit

10.1111/jth.14322 · 2019

Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding

10.1007/s11239-025-03151-w · 2026

Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin

10.1002/cncr.33337 · 2021

Retrospective study of bleeding risk with concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor and anticoagulation